An interventional study of Olive pomace oil and High oleic acid sunflower oil in Healthy and Hypercholesterolemia, sponsored by Instituto de Ciencia y Tecnología de Alimentos y Nutrición. Completed at 1 site in Spain. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-16.
Sponsored by Instituto de Ciencia y Tecnología de Alimentos y Nutrición · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Hypercholesterolemia with a site in Spain — 5 open to participants now, 11 under way, 7 of them phase 3. Hypercholesterolemia · Spain.
Among the 80 studies in Hypercholesterolemia with a site in Spain, this one is the 56th largest by enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2018, is one of 14 with no phase, and was the 59th registered.
1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.
Browse Hypercholesterolemia studies →5 of the 80 studies in Hypercholesterolemia with a site in Spain are open now. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Spain, Germany, Italy
Ages 18+
AstraZeneca · Sites in Spain, United States, Bulgaria and 8 more countries
Ages 18–130
Novartis Pharmaceuticals · Sites in Spain, United States, Argentina and 20 more countries
Ages 6–11
Fundació Eurecat · Sites in Spain
Ages 18+ · Healthy volunteers
University of Valencia · Sites in Spain
Ages 18–80
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 58 Hypercholesterolemia studies recruiting now, 25 (43%) set no upper age limit and 21 (36%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 48 · Phase 4 5
First in 2003; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is below the median of 108 across 979 interventional studies indexed under Hypercholesterolemia.
Median enrollment 300 across the 73 interventional studies, 5,000 across the 7 observational. Of the 66 that completed or were terminated, 44 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 80 have an industry lead sponsor. The 10 most frequent:
Instituto de Ciencia y Tecnología de Alimentos y Nutrición is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Instituto de Ciencia y Tecnología de Alimentos y Nutrición has 2 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
2 of the studies in Hypercholesterolemia with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07619131Phase 3AstraZenecaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. | 2027-07-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 80 studies in Hypercholesterolemia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Healthy and at risk (hypercholesterolemic) subjects consumed during 4 weeks 45 g/d of either olive pomace oil (OPO) or high oleic acid sunflower oil (HOSO) as the only dietary fat in a randomized, crossover trial. The effects on blood lipids, glucose homeostasis, endothelial function, inflammatory cytokines, oxidative stress biomarkers and anthropometry were measured.
This is the first study on the potential health effects of consumption of olive pomace oil.
After a 3-weeks run-in, 34 healthy and 30 hypercholesterolemic subjects were randomized to consume either OPO or HOSO (45 g/d) during 4 weeks, followed by a 3-week wash-out during which volunteers consumed the same amount of normal sunflower oil. During all the study, other dietary sources of fat (oil, nuts, butter, etc.) were restricted. Food intake was monitored by 3-d food records in each intervention stage and volunteers were instructed to maintain their normal physical and dietary habits (except for the changes in the consumption of other oils and fats).
At the beginning and end of each intervention stage, blood and urine samples were obtained, and blood pressure and anthropometric measurements were performed. A complete batch of analysis were performed, including serum lipids, endothelial function (flow mediated dilation (FMD), endothelial nitric oxide synthase (eNOS), vascular (VCAM-1) and intercellular (ICAM-1) cell adhesion molecules, E- and P-selectins), inflammatory and anti-inflammatory cytokines, glucose homeostasis/insulin resistance, antioxidant status and biomarkers of lipid oxidation (malondialdehyde (MDA), LDLox, ferric reducing antioxidant power (FRAP), oxygen radical absorbance capacity (ORAC), ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) quenching capacity) and anthropometry, along with determination of incretins, adipokines, and other clinical and hematological parameters.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intake of 45 g/d of olive pomace oil as the only source of oil in the diet
Other: Olive pomace oil
Intake of 45 g/d of high-oleic sunflower oil as the only source of oil in the diet
Other: High oleic acid sunflower oil
Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
Also known as: OPO
Volunteers consumed during 4 weeks 45 g/d of oleic acid-rich sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
Also known as: HOSO
Blood lipids
Changes on total or LDL-cholesterol levels or triglycerides in at risk (hypercholesterolemic) subjects. No effect on blood lipids expected in healthy (normocholesterolemic ) volunteers
Time frame: 4 weeks
Endothelial function
Changes in the levels of selectins, adhesion molecules or eNOS levels in volunteers
Time frame: 4 weeks
Blood pressure
Changes in systolic/diastolic blood pressure in volunteers
Time frame: 4 weeks
Glucose homeostasis
Modification of fasting blood glucose or insulin levels, decrease in glycosylated hemoglobin (Hb1Ac), homeostasis model assessment (HOMA) of insulin resistance (HOMA-IR) or beta-cell function (HOMA-beta)
Time frame: 4 weeks
Inflammation
Changes in pro-inflammatory cytokines/C-reactive protein (CRP) levels
Time frame: 4 weeks
Oxidative status
Modification in serum antioxidant capacity (FRAP, ABTS, ORAC) and/or decreased levels of biomarkers of lipid oxidation (MDA, LDLox)
Time frame: 4 weeks
Plan to share: No
Ran from Apr 2018 to primary completion in Jul 2018, 3 months.
Of 135 non-industry interventional studies with no phase under Hypercholesterolemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's 3 months is below that.
Counting every sponsor, half of 153 studies reached it within 15 months; a quarter within 6 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto de Ciencia y Tecnología de Alimentos y Nutrición